Target · TREM2
TREM2
Microglial receptor whose loss-of-function increases plaque density; activating antibodies are in early clinical evaluation, with timing-dependent benefit/harm an open question.
All 2 claims
Sorted by confidence. Click any to read the evidence.
AβTREM2BBB
0.78 ATV:TREM2 agonist antibody brain shuttle construct (ATV fused to anti-TREM2 agonist) achieves 50-fold higher brain exposure than unmodified antibody and shows superior microglial activation and plaque reduction in 5xFAD mice compared with anti-TREM2 alone, providing in vivo validation of the ATV platform for TREM2...
Guangxu Wei 1995, Neuron experimental
AβTREM2
0.40 If amyloid containment rather than production is the operative variable, why have anti-amyloid antibodies (e.g., lecanemab) shown any clinical benefit at all?
reviewer:will-blair-bot observational